Insulin therapy in type 2 diabetes: what is the evidence?
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Aim: To systematically review the literature regarding insulin use in patients with type 2 diabetes mellitus Methods: A Medline and Embase search was performed to identify randomized controlled trials (RCT) published in English between 1 January 2000 and 1 April 2008, involving insulin therapy in adults with type 2 diabetes mellitus. The RCTs must comprise at least glycaemic control (glycosylated haemoglobin (HbA1c), postprandial plasma glucose and /or fasting blood glucose (FBG)) and hypoglycaemic events as outcome measurements. Results: The Pubmed search resulted in 943 hits; the Embase search gave 692 hits. A total of 116 RCTs were selected by title or abstract. Eventually 78 trials met the inclusion criteria. The studies were very diverse and of different quality. They comprised all possible insulin regimens with and without combination with oral medication. Continuing metformin and/or sulphonylurea after start of therapy with basal long‐acting insulin results in better glycaemic control with less insulin requirements, less weight gain and less hypoglycaemic events. Long‐acting insulin analogues in combination with oral medication are associated with similar glycaemic control but fewer hypoglycaemic episodes compared with NPH insulin. Most of the trials demonstrated better glycaemic control with premix insulin therapy than with a long‐acting insulin once daily, but premix insulin causes more hypoglycaemic episodes. Analogue premix provides similar HbA1c, but lower postprandial glucose levels compared with human premix, without increase in hypoglycaemic events or weight gain. Drawing conclusions from the limited number of studies concerning basal–bolus regimen seems not possible. Some studies showed that rapid‐acting insulin analogues frequently result in a better HbA1c or postprandial glucose without increase of hypoglycaemia than regular human insulin. Conclusion: A once‐daily basal insulin regimen added to oral medication is an ideal starting point. All next steps, from one to two or even more injections per day should be taken very carefully and in thorough deliberation with the patient, who has to comply with such a regimen for many years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia · doi:10.1007/s00125-007-0911-x · Cited by 447
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414
Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes
Woerle, H. J., Neumann, C., Zschau, S., Tenner, S., Irsigler, A., Schirra, J., Gerich, J. E., & Göke, B. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.11.011 · Cited by 316
Cited by
Semlitsch, T., Engler, J., Siebenhofer, A., Jeitler, K., Berghold, A., & Horvath, K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub4 · Cited by 80
Arnolds, S., Kuglin, B., Kapitza, C., & Heise, T. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02470.x · Cited by 69
Conti, M., Massari, G., Meneghini, E., Pasquino, B., Agosti, B., Chinotti, F., Pintaudi, B., Girelli, A., & Bertuzzi, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030642 · Cited by 21
“Controlling blood glucose levels in patients affected by T2DM using basal insulin therapy and no rapid insulin can be challenging [19].”
BackgroundComparative effectiveness and safety of different basal insulins in a real-world setting
Ji, L., Zhang, P., Zhu, D., Lu, J., Guo, X., Wu, Y., Li, X., Ji, J., Jia, W., Yang, W., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12920 · Cited by 13
“Similar results were observed in previous RCT studies.(7,10,33,34) In the ITT population, the effect of adding 1 specific BI may be either diluted or strengthened by regimen change or by adding prandial insulin during follow-up, which might impact comparison among different insulin treatments.”
Result
Metadata
- Authors
- Van Avendonk, M. J. P., & Rutten, G. E. H. M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2009-04-15
- Volume
- 11
- Issue
- 5
- Pages
- 415-432
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2103231672
- Cited by
- 38
- References
- 14
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin therapy in type 2 diabetes: what is the evidence? https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00981.x
- The paper
- Van Avendonk, M. J. P., & Rutten, G. E. H. M. (2009). Insulin therapy in type 2 diabetes: what is the evidence? Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00981.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.